Supplement Scoop: FDA Wants Your Label Lowdown
Published Date: 2/24/2026
Notice
Summary
The FDA wants to hear from companies that make, package, label, or store dietary supplements about their current manufacturing rules. They’re asking for feedback on how they collect information to make sure supplements are safe and high-quality. If you’re involved in dietary supplements, you’ve got until April 27, 2026, to share your thoughts—no extra costs, just your voice!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Major Recordkeeping Burden for Supplement Makers
Dietary supplement businesses must follow 21 CFR part 111 recordkeeping across many areas (personnel, sanitation, equipment, production controls, quality control, components/packaging, batch records, complaints, etc.). FDA estimates the total annual recordkeeping burden at 929,140 hours (including 279,120 hours for quality control records under §111.140, 279,120 hours for components/packaging records under §111.180, and 204,160 hours for batch production records under §111.260). The Agency also states there are no capital or operating and maintenance costs associated with this collection.
Option to Reduce 100% Ingredient Testing
Under 21 CFR 111.75(a)(1), a manufacturer that currently performs 100% identity testing of incoming dietary ingredients may petition the FDA (under 21 CFR 10.30) to request an exemption to reduce the testing frequency if it demonstrates no material diminution of assurance. FDA estimates the reporting burden for such a petition as 1 response taking 8 hours.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
Previous / Next Documents
Previous: 2026-03588 — Hearing Designation Order Issued to 97.5 Licensee TX, LLC
The FCC is holding a hearing about 97.5 Licensee TX, LLC’s request to transfer control of three El Paso radio stations. They’re checking if the current owner followed the rules, if an unauthorized transfer happened, and if everyone involved is honest and qualified. If you want to join the hearing, you must act by March 26, 2026—this could affect who runs these stations and how they operate.
Next: 2026-03590 — Agency Information Collection Activity Under OMB Review: Bus Testing Program
The Federal Transit Administration is asking for public feedback on its Bus Testing Program paperwork by March 26, 2026. This affects bus manufacturers and testers who provide info to make sure buses are safe and reliable. The goal is to keep the process clear and easy while following government rules—no big cost changes, just smoother info collection.